Promising Drugs for Breast Cancer Tested in Novel Trial at Penn

May 13, 2013

Angela DeMichele, MD, MSCE, an associate professor in the division of Hematology-Oncology in the Abramson Cancer Center, was featured in a CBS3 story about the I-SPY2 trial, which is designed to speed the pace at which new drugs for breast cancer are tested. "The women receive one of the drugs that is best tailored to her tumor, and receives the drug before ever having surgery, so we can see if it's working," said DeMichele, who was interviewed with one of her patients who was treated with investigational drugs along with standard therapies and is now cancer-free. Typically, new medications are first tested on patients with advanced disease, but this trial is creating a new model for testing drugs used prior to surgery among patients with earlier stage cancers, at a time when they have the best chance of producing a cure.

CBS3 segment